[
  {
    "ts": "2026-01-01T06:10:30+00:00",
    "headline": "Jim Cramer Shares Key Caveat For Novo Nordisk (NVO)’s Weight Loss Pill",
    "summary": "We recently published 10 Stocks on Jim Cramer’s Radar. Novo Nordisk A/S (NYSE:NVO) is one of the stocks on Jim Cramer’s radar. Danish pharmaceutical firm Novo Nordisk A/S (NYSE:NVO) scored a major win earlier this month after it secured the Food and Drug Administration’s (FDA) approval for its weight loss pill. The approval made the Wegovy […]",
    "url": "https://finance.yahoo.com/news/jim-cramer-shares-key-caveat-061030070.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "305b0ab3-520f-389a-b0ec-0e6787428e6e",
      "content": {
        "id": "305b0ab3-520f-389a-b0ec-0e6787428e6e",
        "contentType": "STORY",
        "title": "Jim Cramer Shares Key Caveat For Novo Nordisk (NVO)’s Weight Loss Pill",
        "description": "",
        "summary": "We recently published 10 Stocks on Jim Cramer’s Radar. Novo Nordisk A/S (NYSE:NVO) is one of the stocks on Jim Cramer’s radar. Danish pharmaceutical firm Novo Nordisk A/S (NYSE:NVO) scored a major win earlier this month after it secured the Food and Drug Administration’s (FDA) approval for its weight loss pill. The approval made the Wegovy […]",
        "pubDate": "2026-01-01T06:10:30Z",
        "displayTime": "2026-01-01T06:10:30Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/7746a495763c517cd6ea96985a667439",
          "originalWidth": 1920,
          "originalHeight": 1280,
          "caption": "Jim Cramer Shares Key Caveat For Novo Nordisk (NVO)'s Weight Loss Pill ",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/L.y5eHntIJd0XzA2FsxbTA--~B/aD0xMjgwO3c9MTkyMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/insidermonkey.com/7746a495763c517cd6ea96985a667439.cf.webp",
              "width": 1920,
              "height": 1280,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/6ji6jibByYrwJ8.gSBa.ig--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/7746a495763c517cd6ea96985a667439.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/jim-cramer-shares-key-caveat-061030070.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/jim-cramer-shares-key-caveat-061030070.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVO"
            },
            {
              "symbol": "NONOF"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-01T12:45:00+00:00",
    "headline": "Forget Recursion Pharmaceuticals Stock. This Is a Much Better Buy.",
    "summary": "These two companies have very different risk-reward profiles.",
    "url": "https://www.fool.com/investing/2026/01/01/forget-recursion-pharmaceuticals-stock-this-is-a-m/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "ba86c9fd-ab02-36b8-a475-8e916298b0b0",
      "content": {
        "id": "ba86c9fd-ab02-36b8-a475-8e916298b0b0",
        "contentType": "STORY",
        "title": "Forget Recursion Pharmaceuticals Stock. This Is a Much Better Buy.",
        "description": "",
        "summary": "These two companies have very different risk-reward profiles.",
        "pubDate": "2026-01-01T12:45:00Z",
        "displayTime": "2026-01-01T12:45:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/b95191fb3cd42367720b91725a254da4",
          "originalWidth": 1400,
          "originalHeight": 933,
          "caption": "Person working at a desk.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/fGwmoj.DPIgtBSppT54duw--~B/aD05MzM7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/b95191fb3cd42367720b91725a254da4.cf.webp",
              "width": 1400,
              "height": 933,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/lmeU4q9yh127slfelxCCjg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/b95191fb3cd42367720b91725a254da4.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2026/01/01/forget-recursion-pharmaceuticals-stock-this-is-a-m/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/forget-recursion-pharmaceuticals-stock-much-124500110.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "RXRX"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]